CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Akebia Investors of a Lead Plaintiff Deadline of May 13, 2022
NEW YORK, May 9, 2022 /PRNewswire/ -- Attention Akebia Therapeutics, Inc. ("Akebia") (NASDAQ: AKBA) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between June 28, 2018 and September 2, 2020.
If you suffered a loss on your investment in Akebia, contact us about potential recovery by using the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/akebia-therapeutics-inc-loss-submission-form?prid=26890&wire=4
ABOUT THE ACTION: The class action against Akebia includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's lead investigational product candidate, vadadustat, was not as safe in treating non-dialysis dependent chronic kidney disease patients with anemia as defendants had represented; (ii) as a result, defendants overstated the clinical prospects of a Phase 3 clinical program for vadadustat; (iii) accordingly, defendants also overstated vadadustat's overall commercial and regulatory prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
DEADLINE: May 13, 2022
Aggrieved Akebia investors only have until May 13, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: [email protected]
SOURCE The Law Offices of Vincent Wong
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article